Pazopanib - Isotope Labelled Standards
References
FAQ's
References
- Boloor, Amogh; Cheung, Mui; Davis, Ronda; Harris, Philip Anthony; Hinkle, Kevin; Mook, Robert Anthony; Stafford, Jeffery Alan; Veal, James Marti, Pyrimidineamines As Angiogenesis Modulators, Glaxo Group Limited, United Kingdom, EP1343782B1, May 6, 2009
- Liu, David Q.; Chen, Ted K.; McGuire, Michael A.; Kord, Alireza S., Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process, Journal of Pharmaceutical and Biomedical Analysis, Volume: 50, Issue: 2, Pages: 144-150, 2009
Frequently Asked Questions
What are the degradation products of Pazopanib impurities?
The specific degradation products of Pazopanib impurities can vary, but common degradation pathways may involve oxidative processes, hydrolysis, or photodegradation, leading to various byproducts and unreacted compounds.
Are Pazopanib impurities tested for mutagenicity?
Pazopanib impurities are typically tested for mutagenicity to evaluate their potential.
Are there any Pazopanib impurities that are more difficult to identify or control?
Potential isomeric forms or trace-level impurities of Pazopanib can be more challenging to identify and control due to their low concentration or structural similarities with the main compound.
What are the temperature conditions required to store Pazopanib impurities?
Pazopanib impurities are stored at a regulated room temperature of 2-8°C or as specified on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.